Drug – bio-affecting and body treating compositions – Radionuclide or intended radionuclide containing; adjuvant...
Patent
1988-04-06
1991-10-15
Maples, John S.
Drug, bio-affecting and body treating compositions
Radionuclide or intended radionuclide containing; adjuvant...
424 8591, 536 184, 514 8, 530389, 530395, 530399, 530390, 530391, A61K 39395, A61K 3710, A61K 4300, C07H 1500
Patent
active
050573012
ABSTRACT:
Modified cellular substrates are used as linking groups that are recognized as cellular substrates by intracellular metabolic enzymes. The linking groups function to attach a ligand, such as a drug or radionuclide, to a targeting protein, such as an antibody or antibody fragment. The false substrate structure of the linking groups causes increased cellular retention of the linking group/ligand conjugate because the enzymes used for catabolism of the substrate are inhibited by the false substrate structure of the linking group.
REFERENCES:
patent: 3817978 (1974-06-01), Jenkins et al.
patent: 3852413 (1974-12-01), Cammarata
patent: 4126669 (1978-11-01), Rothman et al.
patent: 4202874 (1980-05-01), Akerkar et al.
patent: 4269826 (1981-05-01), Zimmermann et al.
patent: 4275000 (1981-06-01), Ross
patent: 4301140 (1981-11-01), Frank et al.
patent: 4308050 (1981-12-01), Felix
patent: 4331590 (1982-05-01), Bocuslaski et al.
patent: 4356170 (1982-10-01), Jennings et al.
patent: 4385046 (1983-05-01), Milbrath et al.
patent: 4399817 (1983-08-01), Benedict
patent: 4474746 (1984-10-01), Blau et al.
patent: 4507234 (1985-03-01), Kato et al.
patent: 4524059 (1985-06-01), Elmaleh et al.
patent: 4569789 (1986-02-01), Blattler et al.
patent: 4585754 (1986-04-01), Meisner et al.
patent: 4671958 (1987-06-01), Rodwell et al.
patent: 4692434 (1987-09-01), Hertel
patent: 4709016 (1987-11-01), Giese
patent: 4722906 (1988-02-01), Guire
patent: 4732864 (1988-03-01), Tolman
patent: 4741900 (1988-05-01), Alvarez et al.
patent: 4746505 (1988-05-01), Jones et al.
patent: 4771127 (1988-09-01), Cryz et al.
patent: 4793986 (1988-12-01), Serino et al.
patent: 4859449 (1989-08-01), Mattes
European Search Report for Application No. EP/89105876.
Goodman et al., "New Myocardial Imaging Agents: Preparation of 15-(p-[.sup.123 I]-Iodophenyl)-7-Tellurapontadecanoic Acid from Na[.sup.123 I] by a Triazene Decomposition Reaction", in Paras and Thiessen (eds.), The Developing Role of Short-Lived Radio-nuclides in Nuclear Medical Practice, Office of Science and Technical Information, U.S. Dept. of Energy, 1985 [Goodman et al., I].
Liefhold et al., "Synthesis, Labeling, and Pharmacokinetics of .sup.131 I Labeled Phenylene-Iodophenyl-Fatty Acids (PHIPA)", in Sixth Int. Symposium on Radiopharmaceutical Chemistry, pp. 212-14, 1986.
Knapp, Jr. et al., "Development of Radioiodinated Fatty Acids for Applications in Nuclear Cardiology", in Paras and Thiessen (eds.), The Developing Role of Short-Lived Radionuclides in Nuclear Medical Practice, Office of Science and Technical Information, U.S. Dept. of Energy, [Knapp, Jr. et al. I].
Gallagher et al., "Radiopharmaceuticals XXVII. .sup.18 F-Labeled 2-Deoxy-2-Fluoro-D-Glucose as a Radiopharmaceutical for Measuring Regional Myocardial glucose Metabolism in Vivo: Tissue Distribution and Imaging Studies in Animals", J. Nucl. Med. 18:990-996, 1977 [Gallagher et al., I].
Knapp, Jr. et al., "Effect of Tellurium Position on the Myocardial Uptake of Radioiodinated 18-Iodotellura-17-Octadecanoic Acid Analogues", J. Med. Chem. 27:57-63, 1984, [Knapp, Jr. et al., II].
Livni et al., "Beta-methyl[1-.sup.11 C] heptadecanoic Acid: A New Myocardial Metabolic Tracer for Position Emission Tomography", J. Nucl. Med. 23:169-175, 1982.
Elmaleh et al., "Myocardial Imaging with 9-[Te-123m]Telluraheptadecanoic Acid", J. Nucl. Med. 22:994-999, 1981 [Elmleh et al. 1].
Goodman et al., "Synthesis and Evaluation of Radioiodinated Terminal p-Iodophenyl-Substituted .alpha.-and .beta.-Methyl-Branched Fatty Aciods", J. Med. Chem. 27:340-397, 1984 [Goodman et al. II].
Goodman et al., "New Myocardial Imaging Agents: Synthesis of 15-(p-Iodophenyl)-3(R,S)-methylpentadecanoic Acid by Decomposition of a 3,3-(1,5-Pentarediyl)triazene Precursor", J. Org. Chem. 49:2322-2325, 1984 [Goodman et al. III].
Gallagher et al., "Metabolic Trapping as a Principle of Radio-pharmaceutical Design: Some Factors Responsible for the Biodistribution of [.sup.18 F]2-Deoxy-2-Fluoro-D-Glucose", J. Nucl. Med. 19:1154-1161, 1978 [Gallagher et al. II].
Elmaleh et al., "Comparison of .sup.11 C and .sup.14 C-Labeled Fatty Acids and Their .beta.-Methyl Analogs", Int. J. Med. Biol. 10:181-187, 1983 [Elmaleh et al. II].
Pande et al., "Inhibition of Long-Chain Fatty Acid Activation by .alpha.-Bromopalmitate and Phytanate", Biochim. Biophys. Acta. 248:156-166, 1971.
Goodman et al., "Synthesis and Biological Evaluation of 17-[.sup.131 I]Iodo-9-Telluraheptadecanoic Acid, a Potential Myocardial Imaging Agent", J. Med. Chem. 25:613-618, 1982[Goodman et al. IV].
Goodman et al., "A New, Well-Retained Myocardial Imaging Agent: Radioiodinated 15-(p-Iodophenyl)-6-Tollurapntadecanoic Acid", J. Nucl. Med. 23:904-908, 1982 [Goodman et al. V].
Knapp, Jr. et al., "New Myocardial Imaging Agents: Stabilization of Radioiodine as a Terminal Vinyl Iodide Moiety on Tellurium Fatty Acids", J. Med. Chem. 26:1293-300, 1983 [Knapp, Jr. et al. III].
Otto et al., "Radioiodinated Branched-Chain Fatty Acids: Substrates for Beta Oxidation? Concise Communication", J. Nucl. Med. 25:75-80, 1985.
Knapp, Jr. et al., "Effects of Chain Length and Tellurium Position on the Myocardial Uptake of Te-123m Fatty Acids", J. Nucl. Med. 22:988-993, 1981 [Knapp, Jr. et al. IV].
Pittman et al., (J. Biol. Chem., vol. 254, No. 15, Aug. 10, 1979, pp. 6876-6879).
Pittman et al., (Biochem J., vol. 212, pp. 791-800 [1983]).
Hylarides Mark D.
Wilbur Daniel S.
Maples John S.
NeoRx Corporation
Seese Kathryn A.
LandOfFree
Modified cellular substrates used as linkers for increased cell does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modified cellular substrates used as linkers for increased cell , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified cellular substrates used as linkers for increased cell will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-989609